At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIIB Biogen
Trading 05-17 12:58:56 EDT
229.44
-0.60
-0.26%
High230.83Low226.43Vol457.52K
Open229.02D1 Closing230.04Amplitude1.91%
Mkt Cap33.41BTradable Cap33.28BTotal Shares145.60M
T/O104.63MT/O Rate0.32%Tradable Shares145.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Zacks  ·  05-17 22:10
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Biogen: A Balanced View Amidst Setbacks and Alzheimer’s Drug Potential
TIPRANKS  ·  05-17 06:55
Biogen: A Balanced View Amidst Setbacks and Alzheimer’s Drug Potential
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High
MT Newswires  ·  05-17 02:01
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High
Biogen also drops collaboration with Ionis on Angelman syndrome candidate
seekingalpha  ·  05-17 01:47
Biogen also drops collaboration with Ionis on Angelman syndrome candidate
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness
MT Newswires  ·  05-17 00:54
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness
Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk
Dow Jones  ·  05-16 23:52
Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk
BUZZ-Biogen falls after discontinuing development of ALS drug
Reuters  ·  05-16 21:11
BUZZ-Biogen falls after discontinuing development of ALS drug
Biogen and Ionis drop ALS candidate after trial setback
seekingalpha  ·  05-16 21:00
Biogen and Ionis drop ALS candidate after trial setback
AbCellera: If You Build It, Will They Come? Fresh Impetus Required
seekingalpha  ·  05-16 20:39
AbCellera: If You Build It, Will They Come? Fresh Impetus Required
Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis
Dow Jones  ·  05-16 20:05
Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis
BRIEF-Biogen Shares Update on Angelman Syndrome Program
Reuters  ·  05-16 20:03
BRIEF-Biogen Shares Update on Angelman Syndrome Program
UPDATE 1-Biogen, Ionis to discontinue development of ALS drug
Reuters  ·  05-16 19:51
UPDATE 1-Biogen, Ionis to discontinue development of ALS drug
Biogen, Ionis will discontinue development of their ALS drug
Reuters  ·  05-16 19:37
Biogen, Ionis will discontinue development of their ALS drug
Biogen (BIIB) Receives a Buy from Truist Financial
TIPRANKS  ·  05-16 19:36
Biogen (BIIB) Receives a Buy from Truist Financial
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
GlobeNewswire  ·  05-16 11:30
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
AstraZeneca PLC ADR Falls Wednesday, Underperforms Market
Dow Jones  ·  05-16 05:26
AstraZeneca PLC ADR Falls Wednesday, Underperforms Market
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
MT Newswires  ·  05-16 03:52
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
Equity Markets Rise Intraday as Consumer Inflation Cools
MT Newswires  ·  05-16 01:23
Equity Markets Rise Intraday as Consumer Inflation Cools
Eisai projects major growth for Alzheimer's therapy Leqembi
seekingalpha  ·  05-16 00:52
Eisai projects major growth for Alzheimer's therapy Leqembi

Introduction

Company Name.
Biogen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Issue price:
--